Review Article

TIPS Trends in Pharmaceutical Sciences 2021: 7(3): 201-218.

Release of profens from nanofibers: Challenges and opportunities

Farnaz-sadat Fattahi[1*], Tahereh Zamani[2]

[1]Department of Textile Engineering, Isfahan University of Technology, Isfahan, Iran.
[2]The Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.

Abstract

Nanofibrous meshes refer to the structures made of ultra-fine polymeric fibers. Because of nanometer measure size with an excessive strength/weight ratio, they are actual suitable as a nanosystem for delivering drug molecules. Drug molecules which mixed in nanofibers, can be released from the surrounding environment by means of various mechanisms in different manners (burst release, sustainable release and tunable release). Nanofibers can be used by way of release rate controlling strategies as proper delivery structures for drug molecules.The objective of this review is to highpoint the capacity of nanofibers as novel releasing substances for profens (Propionic acid derivative drugs including Carprofen; Naproxen; Fenoprofen; Flurbiprofen; Ibuprofen; Ketoprofen and Tiaprofenic acid). The profens are a class of nonselective, nonsteroidal anti-inflammatory drugs (NSAIDs). These drug molecules are derivatives of 2-phenylpropanoic acid. All contain a chiral center resulting in the formation of two enantiomers (R and S) of each profen. In this review, full information will be reported about the new progresses for release behaviors of profen molecules form the novel nanofibrous delivery systems. The drug releasing kinetics of profen molecules from nanofibers will be described briefly. The authors use more than 80 articles , books and thesis published in the case of nanofibrous profens delivery and releasing systems.

Keywords: Nanofibers, Release characteristic, Propionic acid derivative drugs, Kinetic, Sustainable release.

1. Introduction

In new periods, various investigators have paid more consideration to drug delivery systems (DDS), that have been established as a novel meaning of releasing drug molecules by exact dose and suitable management (1).

Drug is a chemical substance that used in the treatment, cure, prevention or diagnosis of daises or used to otherwise enhance physical or mental wellbeing. Drugs extending from herbal extras, antibiotics and anticancers to proteins, DNA, RNA, living cells, several nanoparticles, nanotubes, nanorods and numerous growth factors which can be combined with nanofibers for producing nanofibrous drug delivery systems (2). It will be hopeful in medical requests having great efficiency and care of drugs, and great agreement of patients. Numerous scientists have discovered the procedure of nanotechnology, explicitly nanofibers, as drug delivery systems for transdermal uses. Nanofibers can be used to deliver drugs and are capable of controlled release for a continued period of time (3).

Corresponding Author: Farnaz-sadat Fattahi, Department of Textile Engineering, Isfahan University of Technology, Isfahan, Iran.
Email: fattahi_farnaz@yahoo.com

2. Controlling the drug release from nanofibers

The releasing of the drug from nanofibers is principally via two mechanisms which are displayed in figure 1 (4).

There are three chief styles for releasing trends of drug molecules from nanofibers that will be displayed in Figure 2 .

Received: 08/03/2021; Accepted: 01/05/2021



Figure 1. Mechanisms of controlling the drug release from nanofibers (5).

For the delivery of antibiotic drugs, a great initial burst is reflected a benefit since it is essential for eliminating the interfering bacteria previously they implore to proliferate. Furthermore, direct incorporation of drug molecules in nanofibers might possibly cause undesired burst releasing. On the other hand, the drug release kinetics can be modified by means of the selecting of polymer and controlling over the nanofiber diameter, porosity, geometry, and morphology with regulating the numerous processing variables during nanofibers production (6, 7).

Nanofibers can be used by way of release rate controlling strategies. Drug release from nano fibers could be because of desorption of drug from the surface layer, diffusion from pores and or matrix degradation (8, 9). These all procedures of drug release are possible to get affected by select of inactive (polymer or other material), porosity, morphology, and geometry of nano fibers (10, 11). Usually smaller the diameter of nanofiber quicker the release rate is reflected from it based on the statement that reduced diameter fiber has advanced surface layer area and dissolution rate(12, 13). Advanced conclusions recommended that drug release cannot be only run by means of diameter and simultaneously influence of porosity is to be considered. It is repeatedly revealed that thicker nanofibers with very high porosity releasing drug quicker as compared to thinner fibers with low porosity (14, 15).

3. Analyzing of the drug releasing kinetics

Drug molecules mixed in nanofibers can be released from the surrounding environment by means of a blend of various mechanisms (16). Drug molecules on the nanofibre surfaces can be dissolved and spread out of the nanofibers sheath as it is entered with body fluids. Elimination of molecule drugs on fiber surface regularly matches



Figure 2. Release behaviors of drug molecules from nanofibers.

to the burst phase of drug releasing. The amount of burst releasing might increase with the surface area on the nanofiber, so fibers with smaller fiber diameter or upper ratio of holes can have rapider burst release (17).

For the assessment of the drug releasing kinetics and the determining of the mechanism in nanofibers, generally some equations are used like:

Peppas korsmeyer equation,
Semi empirical releasing(srikar) model,
Crank model, siepmann model,
Higuchi equation,
Siepmann and peppas model
Hopfenberg model (18, 19).

4. Drug related factors affecting drug releasing

Drug associated factors affecting its releasing form nanofibers are listed in next paragraphs (20).

Drug loading

Generally, higher drug loading is connected with the faster release (21).

Molecular weight of drug

Low molecular weight drugs are recognized for their fast release rate (22).

Physical state of drug: The crystalline arrangement of the drug becomes deposited on nanofiber surface and offers burst release, whereas amorphous arrangement gets deposited deeper inside and get released in a sustained style (23, 24).

Solubility of drug: Drug—polymer interactions.(Chemical or physical interactions) (25).

5. Nanofibers related factors affecting drug releasing

Nanofibers related parameters affecting drug releasing form them are reported in next section (26).

Randomization of nanofibers aligment: Nanofiber alignment is a various factor recognized to mark drug release and generally randomized design is associated with quicker drug release owing to improved affinity of water uptake (27).

Thickness of nanofibers: The releasing of drug molecules are in reverse associated with the fiber diameters. Higher fiber diameter enhances the space that drug molecules placed in the central of fibers which must diffuse from side to side for reaching the edge of the fiber . This mechanism extends release times (28, 29).

Cristalinity of nanofibers

Porosity ratio of nanofibers: The porosity of nanofibers appears to affect the releasing process. A greater porosity might increase the amount of fluid that absorbs to the nanofibers and therefore quicken the releasing. Nonetheless this result might have been repressed with other parameters like the amount of hydrophilicity of nanofibers. Also the size of pores and total volume of pores meaningfully influences the diffusion of the liquid which are absorbed on the nanofibers (30).

Specific surface area of nanofibers: Upper specific surface area delivers a greater space for communication with the nearby fluid and resulting quicker releasing of drug molecules (31, 32).

Also the fabrication method of the nanofibers plays an important character in the drug re-



Figure 3. Propionic Acid Derivative Drugs (Profens) : General structures of R- and S-profens.(The chiral centers are shown*).

Table 1. Chemical structures and physical/chemical properties of the studied profens (34).

Drug	Structure	IUPAC Name	Mol. Mass, g/mol	Tm, ˚C	pKa	logP
Ibuprofen		Iso-butylphenylpropionic acid	206	78	4.9	4.0
Ketoprofen		2-(3-benzoylphenyl)- propanoic acid	254	94	3.9	3.1
Flurbiprofen		2-(3-fluoro-4-phenylphenyl)-propanoic acid	244	111	4.4	4.2
Naproxen		(2S)-2-(6-methoxynaphthalen-2-yl)-propanoic acid	230	155	4.2	3.3
Chamazulene carboxylic acid (1)	—	A natural profen with anti-inflammatory activity and a degradation product of proazulenic sesquiterpene lactones, e.g., matricin.	—	—	—	—

leasing procedure.

6. Propionic Acid Derivative Drugs (Profens)

The profens are a group of anti-inflammatory drugs. They reduce pain, body temperature in fever, signs of inflammation, and, in mice, slow the development of cancers. The profens are derivatives of 2-phenylpropanoic acid. All contain a chiral center resulting in the formation of two enantiomers (R and S) of each profen (Figure 3). The profens are accessible regularly as their racemates, viz., equal mixtures of the R and S stereoisomers (33).

There are a large number of profens available commercially including: Carprofen; Naproxen; Fenoprofen; Flurbiprofen; Ibuprofen; Ketoprofen; Tiaprofenic acid. In this review paper only some of them are investigated which are seen in Table 1 (34).

6. Release characteristics of propionic acid derivative drugs (profens) from nanofibers

In a novel work, PLGA/ibuprofen nanofibers were electrospun into sandwich scaffolds. Ibuprofen molecules have a tendency for aggregating on the surface layer of nanofibres, so initial burst releasing is occurred throughout implantation. But the sandwiched scaffolds were expected to delay the diffusion of ibuprofen into liquids and reduce the initial burst release. These scaffolds displayed meaningfully a reduced initial burst of ibuprofen releasing in the first hour (35).

Hyaluronic acid/ibuprofen nanofibers were fabricated with electrospinning method. Sustained release of drug molecules from all nanofbers was detected throughout the initial day by 40-60% of ibuprofen molecule releasing after first day (36).

Gliadin/ibuprofen nanofibers were produced. In vitro experiments confirmed that the gliadin nanofibers with heterogeneous drug dispersal had less preliminary burst ibuprofen release and an extended time period releasing of 16 hours, signifying an improved sustained drug release profile than those nanofibers having a homogeneous drug dispersal that had plain initial burst release and a shorter release time period of 8 hour. The various ibuprofen dispersals have operated the different release performances of the loaded ibuprofen molecules, and therefore caused the dissimilar drug sustained release profiles (37).

PLA/ibuprofen nanofibers holding 10, 20, or 30 wt % drug were made. Two styles were seen while studying the release profiles. First, an increased temperature (37 °C) produced a superior release of ibuprofen from the nanofibers as compared to room temperature. Second, the 30 wt % ibuprofen overloaded nanofibers at 37˚C manufactured the highest ibuprofen release (~0.25 mg at 336 hours). At both room temperature and 37 ˚C,

the results showed that a direct correlation occurred between ibuprofen concentration in the nanofibers and the quantity of ibuprofen released. PLGA/ibuprofen nanofibrous were designed. The ibuprofen releasing mechanism is combined of degradation and diffusion. Practically 30% of loaded ibuprofen released in around 8 hours without any initial burst release and then 50% of entire ibuprofen has been released throughout only 4 hours (38).

Polyvinylpyrrolidone/ibuprofen nanofibrous mats were constructed by means of an electrospinning method. The results specified that the ibuprofen molecules had respectable compatibility with the polymer and that ibuprofen was well dispersed in the nanofibers as an amorphous physical form (39).

Cellulose acetate/poly(vinyl pyrrolidone)/ibuprofen nanofibers were produced. These nanofibers showed a 3 phase releasing profile, an initial burst release, a succulents decelerating release and a constant release. Throughout the burst release phase, over 28 wt% of ibuprofen molecules were diffused from nanofibers that were owing to the distribution of ibuprofen molecules on the great surface of the nanofibers. At the succedent decelerating release phase, ibuprofen molecules in the internal of nanofibers diffused onto nanofibers surfaces. Through this procedure, ibuprofen molecules needed to overcome the Van der Waals' force (or dispersion forces) produced between ibuprofen molecules and polymer matrix that reduced ibuprofen diffuse rate. In the latest release phase, the small concentration difference of ibuprofen between receptor solution and nanofibers made the releasing of ibuprofen became more problematic (40).

PLLA/ibuprofen nanofibers which have small amount of Ag nanoparticles were fabricated. The *in vitro* drug releasing analysis indicated a sustained release of Ag ions and ibuprofen molecules from the nanofibers. Throughout the first 2 days, burst releasing of ibuprofen from the nanofibers was 49.5%, followed by a sustained releasing in the following 10 days. Briefly, ibuprofen releasing performance depends chiefly on polymer matrix degradation, drug diffusion and Ag releasing (41).

In another work, the Poly(N-isopropylacrylamide)/Poly(ε-caprolactone)/ibuprofen nanofibers were constructed with Tran et al. These nanofibers confirmed a variable and controlled releasing at both room and higher temperature. The rate at 22 °C is 75% faster compared to that at 34 °C. The results showed that 1 μmol of ibuprofen was rapidly released from these nanofibers in the first hour at 22 °C, and then the rest drug was released at a considerable slower rate, 0.05 μmol hr^{-1}. Completely, 24% ibuprofen was released in four hours. In compare, ibuprofen was released at a more manageable style while the temperature was improved to 34 °C. The average release rate was ~0.2 μmol hr^{-1} and ~0.4 μmol ibuprofen was released in the first one hour. Only 17% ibuprofen was released in 4 hours. This occurrence can be described with the great water solubility of Poly(N-isopropylacrylamide) when the temperature was below its LCST (32 °C), leading to the rapid ibuprofen releasing from the polymeric matrix. Though, Poly(N-isopropylacrylamide) converts greatly hydrophobic after temperature was above its LCST. Therefore Poly(N-isopropylacrylamide) functions similar a drug depot to forbid the rapid release of hydrophobic ibuprofen molecules, resulting in the comparatively more manageable release style (42).

In a different investigation, the PLLA/PLGA/ibuprofen nanofibers were prepared. The outcomes of an *in vitro* ibuprofen releasing displayed a burst release throughout the first 2 days with high initial ibuprofen amount. This initial phase was followed by a sustained release stage from nanfibres during the subsequent 10 days (43).

PLA/ibuprofen nanofibers were created. Two tendencies were detected while examining the ibuprofen release profiles. In the first stage, an increased temperature (37 °C) produced a superior releasing of drug from the nanofibers as compared to room temperature. In the second stage, PLA/ibuprofen (30%) nanofibers at 37 °C produced the maximum drug releasing. In both room temperature and 37 °C, the statistics recommended that a direct association be presented between ibuprofen amount in the nanofibers and the quantity of drug molecules released (44).

Cellulose acetate/Poly(vinylpyrrolidone)/ibuprofen nanofibers were manufactured. These structures samples showed continued and steadily

Table 2. Drug release behaviors of profens from nanofibrous mats.

Material	Content load	Method	*In vitro* study		Ref
			Ibuprofen release		
			Burst release	Sustained release	
Cellulose acetate solved in acetone/DMAc	Naproxen 9.39%	Mixing	40% (in 2.5 hours)	100% (in 25 hours)	(48)
Polyvinylpyrrolidone solved in ethanol	ketoprofen	Mixing	100% (in 4 minutes)	---	(49)
Poly(vinyl alcohol) solved in deionized water	ketoprofen	Mixing	58.43% (in 2 hours)	83.82% (in 14 days)	(50)
Polyethylene oxide solved in methanol and water vapor; Silk and collagen solved in methanol and water vapor.	Polyethylene oxide containing Flurbiprofen as sheath with silk and collagen containing Vancomycin as core	Evaporation and coaxial process	33.1 µg/cm2 Flurbiprofen (in 1 day)+9.0 µg/cm2 Vancomycin (in 1 days)	72.2 µg/cm2 Flurbiprofen (in 9 days)+33.4 µg/cm2 Vancomycin (in 17 days)	(51)
Poly(N-vinylcaprolactam) solved in distilled water and ethanol	Ketoprofen 10%	Mixing	84% (in 4 minutes) at 20˚C80% (in 4 minutes) at 42˚C	98% (in 2 hours) at 20˚C100% (in 2 hours) at 42˚C	(52)
Poly(vinyl pyrrolidone) solved in EtOH and DMF;Poly(lactic-co-glycolic acid) solved in dichloromethane and DMF	Poly(lactic-co-glycolic acid) as sheath with Poly(vinyl pyrrolidone) containing Flurbiprofen 6% as core	Mixing and coaxial process	70% (in 24 hours)	85% (in 10 days)	(53)
Chitosan and polyaniline solved in acetic acid	Ketoprofen	Mixing	50% (in 24 hours) in pH~2	73% (in 4 days) in pH~2	(54)
			70% (in 24 hours) in pH~6.7	90% (in 4 days) in pH~6.7	
			72% (in 24 hours) in pH~7.4	97% (in 4 days) in pH~7.4	
Poly(vinylpyrrolidone) and zein solved in ethanol and water	Ketoprofen	Mixing and sequential process	32% (in 1 hour)	98% (in 16 hours)	(55)
Chitosan solved in acetic acid and water;	Naproxen 5%	Mixing	75% (in 10 minutes)	95% (in 4 hours)	(56)
Polyacrylic acid solved in sodium chloride and β-cyclodextrin;			25% (in 5 minutes)	30% (in 4 hours)	
Poly(caprolactone) solved in acetic acid and formic acid			50% (in 2 minutes)	95% (in 4 hours)	
Poly(vinyl alcohol) solved in water and phosphoric acid;	Naproxen 5%		25% (in 5 minutes)	38% (in 4 hours)	
	Naproxen 10%		40% (in 2 minutes)	48% (in 4 hours)	
	Naproxen 30%		50% (in 2 minutes)	70% (in 4 hours)	
Poly(lactic-co-glycolic acid) solved in N,N-dimethylformamide and tetrahydrofuran	Ibuprofen 5%	Mixing	23% (in 5 days)	80% (in 63 days)	(57)
Polyvinylpyrrolidone and ethyl cellulose solved in ethanol	Naproxen 20%	Mixing	30% (in 12 hours)	90% (in 3 days)	(58)
Pulp cellulose added to melted [BMIM]Cl	Ibuprofen 2%	Mixing and dry–wet process	48% (in 50 minutes) (irrespective of its content)	52% (in 8 hours) (irrespective of its content)	(59)
	Ibuprofen 3%				

Aluminum oxide added to distilled water and 2-butanol	Ibuprofen 25%	Sol–gel	68% (in 10 minutes)	70% (in 7 hours)	(60)
	Ibuprofen 50%		73% (in 10 minutes)	80% (in 7 hours)	
Poly(vinylpyrrolidone) solved in ethanol	Ibuprofen 10%	Pressurized Gyration	68% (in 10 minutes)	100% (in 10 hours)	(61)
Gelatin solved in acetic acid+Poly(lactic acid) solved in chloroform +Hydroxyapatite solved in water	Ibuprofen 33.2%	Mixing	30% (in 3 hours)	77±3.4(in 3 days)	(62)
	Ibuprofen 38.9%		30% (in 3 hours)	87.2±3.4% (in 3 days)	
	Ibuprofen 41.2%		35% (in 3 hours)	81.3±4.6%(in 3 days)	
	Ibuprofen 45.3%		40% (in 3 hours)	92.1±2.8%(in 3 days)	
	Ibuprofen 58.2%		50% (in 3 hours)	95.8±2.1%(in 3 days)	
Poly(vinyl alcohol),Chitosan,ß-cyclodextrins	Ibuprofen	Supercritical carbon dioxide assisted phase inversion	60% (in 3 hours)	90% (in 24 hours)	(63)
Zein solved in methanoic acid	Ibuprofen	Blending	0.05 mg/ml-1 (in 90 min)	---	(64)
Poly(lactic acid) solved in dimethylformamide and chloroform	Ibuprofen 10%	Mixing	0.05 mg (in 1 day)	0.07 mg (in 12 days)	(44)
	Ibuprofen 20%		0.11 mg (in 1 day)	0.13 mg (in 12 days)	
	Ibuprofen 30%		0.21 mg (in 1 day)	0.25 mg (in 12 days)	
Cellulose Acetate solved in N,N-dimethylacetamide and acetone	Ibuprofen	Mixing	7.7% (in 4 hours)	---	(65)
Poly(caprolactone) solved in dichloromethyl and dimethyl formamide	Ibuprofen 10%	Mixing	98% (in 2 hours)	---	(66)
Poly(L-lactide) solved in dichloromethane and N,N-dimethylformamide	Ibuprofen 3.87 ± 0.31%	Mixing	15% (in 2 hours) in pH~5	30% (in 2 days) in pH~5	(67)
			10% (in 6 hours) in pH~7.4	20% (in 2 days) in pH~7.4	
Silk suture immersed in normal saline	Ibuprofen	Deposition on filaments and immersion	0.75/µg cm-1 (in 4 hours)	1.40/µg cm-1 (in 10 days)	(68)
Poly(l-lactic acid) solved in dichloromethane and N, N-dimethylformamide	Ibuprofen 3.91±0.22%	Mixing	40% (in 6 days)	80% (in 35 days)	(69)
Poly(lactide-coglycolide) solved in dichloromethane	Ibuprofen 10%	Mixing	1.6 µ moles (in 1 hour)	---	(70)
Cellulose Acetate solved in acetone/DMAc	Ibuprofen 7.1%	Mixing	20% (in 1 hour)	80% (in 1 day)	(71)
Poly(lactide-coglycolide) and poly(ethylene glycol)-g-chitosan solved in N,N-dimethylformamide	Ibuprofen 5%	Mixing	22% (in 1 day)	70% (in 16 days)	(72)
Poly(lactide-coglycolide) solved in N,N-dimethylformamide	Ibuprofen 5%	Mixing	45% (in 1 day)	100% (in 12 days)	
Poly(lactic-co-glycolic acid) solved in N,N-dimethylformamide and tetrahydrofuran	No load	Mixing	---	---	(57)
	Ibuprofen 5%		25% (in 3 days)	80%(in 45 days)	

Poly(vinyl pyrrolidone) and Lysine solved in milli-Q water	Ibuprofen 5%	Mixing	30% (in 1 day) in pH~5 27.5% (in 1 day) in pH~8	45.09 ± 4.02% (in 1 day) in pH~5 29.17 ± 4.29% (in 1 day) in pH ~8	(73)
Polyvinylpyrrolidone solved in ethanol	No load Ibuprofen 7.5% Ibuprofen 15%	Mixing	---	---	(39)
Cellulose acetate and poly(vinyl pyrrolidone) solved in acetone and DMAc	Ibuprofen 20%	Mixing	30% (in 1 hour)	95% (in 1 day)	(40)
Gliadin solved in 1,1,1,3,3,3-hexafluoro-2-propanol and trifluoroacetic; Cellulose acetate solved in acetone and acetic acid	Cellulose acetate 0% Cellulose acetate 1% Cellulose acetate 3% Cellulose acetate 5% as sheath with gliadin containing Ibuprofen as core	Mixing and triaxial process; Mixing and coaxial process	34.2±4.5%(in1hour) 8.3±4.6% (in 1 hour) 5.4 ±4.1 (in 1 hour) 2.7± 3.1% (in 1 hour)	100% (in 2 days) (irrespective of its content)	(74)
Polyvinylpyrrolidone solved in distilled water	Ibuprofen 431.7 ± 39.7 µg/mL + 145.5 ± 5.6 µg/mL acetylsalicylic acid Ibuprofen 528.3 ± 24.7 µg/mL + 168.3 ±7.3 µg/mL acetylsalicylic acid	Mixing	---	---	(75)
Poly(caprolactone) solved in chloroform and acetone	Ibuprofen 9.1% Ibuprofen 13% Ibuprofen 23.1% Ibuprofen 28.6% Ibuprofen 33.3% Ibuprofen 37.5%	Mixing	72% (in 1 hour) 95% (in 1 hour) 87% (in 1 hour) 80% (in 1 hour) 83% (in 1 hour) 68% (in 1 hour)	100% (in 5 days) (irrespective of its content)	(46)
Poly(caprolactone) solved in dichloromethane and acetone	Ibuprofen 4.59% Ibuprofen 2.29%	Mixing	73% (in 1 hour) 40% (in 1 hour)	75% (in 1 day) 80% (in 1 day)	(47)
Poly(l-lactic acid) solved in dichloromethane and N,N-dimethlformamide	No load Ag 4% Ag 4%+ Ibuprofen 4% Ag 8%	Mixing	--- 23.5% Ag (in 2 days) 49.5% Ibuprofen (in 2 days)+32.7% Ag (in 2 days) 35.9% Ag (in 2 days)	--- 48% Ag (in 10 days) 88% Ibuprofen (in 10 days)+72% Ag (in 10 days) 88% Ag (in 10 days)	(41)
Poly(lactic-co-glycolic acid) and Poly(caprolactone) solved in dichloromethane and N,N-Dimethylformamide	Ibuprofen 5% Ibuprofen 10% Ibuprofen 15%	Mixing	75% (in 24 hours) 78% (in 24 hours) 85% (in 24 hours)	88% (in 13 days) 90% (in 13 days) 96% (in 13 days)	(35)
Gliadin solved in 1,1,1,3,3,3-hexafluoro-2-propanol	Gliadin as sheath containing Ibuprofen 6.25% Ibuprofen 11.76% as core	Mixing and traditional co-axial process	30% (in 2 hours) 35% (in 2 hours)	95% (in 1 day)	(37)
Poly(caprolactone) solved in dichloromethane and acetone	Ibuprofen 2% Ibuprofen 5%	Mixing	40% (in 1 hour) 72% (in 1 hour)	75% (in 1 day) 90% (in 1 day)	(47)

Poly(ethylene glycol) and Poly(caprolactone) solved in dichloromethane and N,N-Dimethylformamide	Poly(ethylene glycol) / Poly(caprolactone) containing Ag as sheath with hyaluronic acid containing Ibuprofen 0% Ibuprofen 10% Ibuprofen 30% Ibuprofen 50% as core	Mixing and core/shell process	50% Ibuprofen (in 8 hours) (irrespective of its content)+80% hyaluronic acid (in 4 days) +78-81% Ag (in 4 days)	50% Ibuprofen (in 21 days) (irrespective of its content) +80% hyaluronic acid (in 17 days) +19-22% Ag (in 17 days)	(76)
Hyaluronic Acid solved in formic acid	Ibuprofen 0% Ibuprofen 20% Ibuprofen 30% Ibuprofen 40%	Mixing	--- 58% (in 24 hours) 52% (in 24 hours) 41% (in 24 hours)	--- 72% (in 20 days) 62% (in 20 days) 60% (in 20 days)	(36)
Poly (L-lactic acid) solved in dichloromethane	No load Ibuprofen	Mixing	--- 46% (in 12 hours)	--- 54% (in 20 days)	(77)
Poly(L-lactic acid)/Polyethylene glycol solved in dichloromethane and acetone	Ibuprofen 0% Ibuprofen 2% Ibuprofen 6% Ibuprofen 10%	Mixing	--- 38% (in 2 days) 47% (in 2 days) 62% (in 2 days)	--- 52% (in 18 days) 48% (in 18 days) 36% (in 18 days)	(78)

increasing release profiles (45). Polycaprolactone/ibuprofen nanofibers were prepared with Potrcˇ *et al* (46).

The releasing of ibuprofen from the PCL nanofibers was fast, reaching about 96% of the overall ibuprofen release in the first 4 hours from the nanofibers. The drug release rates from the PCL nanofibers loaded with various quantities of ibuprofen were not meaningfully different, representing that the changes in the nanofiber diameters and the surface morphology did not affect the release of the ibuprofen (46). A drug release test *in vitro*

Table 3. Physical characteristics of profen loaded nanofibrous mats.

Profen loaded nanofibrous mats	Ultimate stress(MPa)	Ultimate strain(%)	Young's modulus(MPa)	Ref
Poly(vinylpyrrolidone) + zein+ ketoprofen	12	14	---	(55)
Poly(lactic-co-glycolic acid) + Ibuprofen	---	140	---	(57)
Zein + Ibuprofen	0.6	99.7	---	(64)
Cellulose Acetate + Ibuprofen	---	34.36	---	(65)
Gelatin+Ibuprofen	0.8±0.1	---	1.5-2.0	(79)
Hyaluronic Acid+ 20% Ibuprofen	0.63 ± 0.53	61.46 ± 11.42	9.42 ± 0.83	(36)
Hyaluronic Acid+ 30% Ibuprofen	0.94±0.89	81.22 ± 8.23	10.57 ± 0.84	
Hyaluronic Acid+ 40% Ibuprofen	1.43±0.13	90.11 ± 8.75	14.16 ± 1.25	
Poly(lactic-co-glycolic acid) + Poly(caprolactone)+ 5% Ibuprofen	2.6	165	---	(35)
Poly(lactic-co-glycolic acid) + Poly(caprolactone)+ 10% Ibuprofen	2.2	170	---	
Poly(lactic-co-glycolic acid) + Poly(caprolactone)+ 15% Ibuprofen	1.7	180	---	
Poly(lactic-co-glycolic acid) + Poly(caprolactone)	2.2	170	---	
Poly(lactic-co-glycolic acid) + Ibuprofen	11.73±4.43	76.63±21.53	---	(38)

Poly(l-lactic acid)+Polyethylene glycol+ 2%Ibuprofen	3.42 ± 0.36	73.2 ± 3.6	60.4±3.9	(35)
Poly(l-lactic acid)+Polyethylene glycol+ 6%Ibuprofen	3.13 ± 0.38	65.7 ± 3.2	65.8 ±5.1	
Poly(l-lactic acid)+Polyethylene glycol+10%Ibuprofen	2.89 ± 0.31	55.6 ± 4.2	69.3 ±4.6	
Poly(lactic-co-glycolic acid) +Ibuprofen	---	---	---	

showed that the release rate of ibuprofen and ketoprofen was slow in PCL nanofibers loaded with drug–layered double hydroxide nanoparticles. After 5 days, only 44-48% of ibuprofen was released, whereas the release of ketoprofen was 20-25%. All nanofibers could release the drug after 5 days (47).

Release behavior of profens from nanofibrous drug delivery systems will be described in Table 2.

7. Physical aspects of profen loaded nanofibrous mats

Phisycal properties of profen loaded nanofibrous mats will be reported in Table 3.

8. Structural characteristics of profen loaded nanofibrous meshes

Table 4. Structural characteristics of profen loaded nanofibrous mats.

Ibuprofen loaded nanostructure mats	Sample thickness (nm)	Pore size(µm)	Weight (mg/cm2)	Porosity(%)	Water contact angle(˚)	Density (g/cm3)	Degree of swelling (%)	Ref
Cellulose Acetate + Naproxen	409.3 ± 152.5	---	---	---	---	---	---	(48)
Poly(ethylene glycole) + Silk + Collagen + Flurbiprofen + Vancomycin	422 ± 74	---	---	---	---	---	---	(51)
Poly(lactic-co-glycolic acid) + Flurbiprofen	942	---	---	---	113	---	---	(53)
Poly(vinyl pyrrolidone) + Poly(lactic-co-glycolic acid) + Flurbiprofen	286	---	---	---	78	---	---	
Polyvinylpyrrolidone +Ethyl cellulose+20% Naproxen	409±89	---	---	---	---	---	---	(58)
Poly(vinylpyrrolidone) + 10% Ibuprofen	1500	---	---	---	---	---	---	
Poly(vinyl alcohol)+Chitosan+ß-cyclodextrins+Ibuprofen	---	0.7±0.3	---	37±1	---	---	---	(63)
Zein + Ibuprofen	605.6	---	---	---	---	---	---	(64)
Poly(lactic acid) + Ibuprofen 30%	585.38±131.51	---	0.69	---	---	---	---	(44)
Poly(lactic acid) + Ibuprofen 20%	478.31±167.61	---	0.67	---	87.9	---	---	
Poly(lactic acid) + Ibuprofen 10%	329.11±249.62	---	0.428	---	---	---	---	
Cellulose Acetate + Ibuprofen	533.5	---	---	---	---	---	---	(65)
Poly(caprolactone) + Ibuprofen 10%	374 ± 89	---	---	---	---	---	---	(66)
Silk + Ibuprofen	290 ±27	---	---	---	---	---	---	(68)
Poly(L-lactide) + Ibuprofen 3.87 ± 0.31%	1420	---	---	---	---	---	---	(67)
Poly(l-lactic acid) + Ibuprofen 3.91±0.22%	1350 ± 280	---	---	---	---	---	---	(69)
Hydroxypropyl-ß-cyclodextrin + Ibuprofen	180±95	---	---	---	---	---	---	(80)
Cellulose Acetate + Ibuprofen 7.1%	297 ± 14	---	---	---	---	---	600%	(71)
Hydroxyapatite+ Ibuprofen	---	---	---	85	---	1.40		(79)

Poly(caprolactone)+Ibuprofen 9.1%	465± 88	---	---	---	---	---	---	(46)
Poly(caprolactone)+Ibuprofen 13%	454± 83	---	---	---	---	---	---	
Poly(caprolactone)+Ibuprofen 23.1%	593± 105	---	---	---	---	---	---	
Poly(caprolactone)+Ibuprofen 28.6%	568± 97	---	---	---	---	---	---	
Poly(caprolactone)+Ibuprofen 33.3%	582 ± 109	---		---	---	---	---	
Poly(caprolactone)+Ibuprofen 37.5%	686 ± 196	---		---	---	---	---	
Hyaluronic Acid+ 20% Ibuprofen	520 ± 16	---		---	---	---	---	(36)
Hyaluronic Acid+ 30% Ibuprofen	580 ± 17	---		---	---	---	---	
Hyaluronic Acid+ 40% Ibuprofen	630 ± 21	---		---	---	---	---	
Poly(l-lactic acid)	1020 ± 26	---		---	131.3° ± 3.1°	---	---	(41)
Poly(l-lactic acid) + Ag 4%	1140 ± 24	---		---	125.1° ± 4.1°	---	---	
Poly(l-lactic acid) + Ag 4%+ Ibuprofen 4%	1210 ± 37	---		---	126.8° ± 3.9°	---	---	
Poly(l-lactic acid) + Ag 8%	1180 ± 42	---		---	118.4° ± 2.7°	---	---	
Poly(lactic-co-glycolic acid) + Poly(caprolactone)+ 5% Ibuprofen	910±61	---		---	133.5	---	---	(35)
Poly(lactic-co-glycolic acid) + Poly(caprolactone)+ 10% Ibuprofen	1150±59	---		---	134.2	---	---	
Poly(lactic-co-glycolic acid) + Poly(caprolactone)+ 15% Ibuprofen	1150±59	---		---	134.2	---	---	
Poly(lactic-co-glycolic acid) + Poly(caprolactone)	860±40	---		---	135.9	---	---	
Cellulose acetate/Poly(vinylpyrrolidone) +Ibuprofen	385 ± 58	---		---	---	---	---	(45)
Poly (lactic acid) + 10% Ibuprofen	329.116 ± 249.62	---		---	---	---	---	(44)
Poly (lactic acid) + 20% Ibuprofen	478.316 ± 167.61	---		---	116.3	---	---	
Poly (lactic acid) + 30% Ibuprofen	585.386 ± 131.51	---		---	—	---	---	
Poly (ε-caprolactone)+ 10% Ibuprofen	1733	---		---	—	---	---	(42)
Poly (ε-caprolactone)+Poly(N-isopropylacrylamide)+Ibuprofen	551	---		---	—	---	---	
Poly(N-isopropylacrylamide)/ Ibuprofen	470	---		---	---	---	---	
Poly(l-lactic acid)+Polyethylene glycol+ 2% Ibuprofen	1.40 ± 0.52	---		67.5 ± 5.8	119.5 ± 3.1	---	---	
Poly(l-lactic acid)+Polyethylene glycol+ 6% Ibuprofen	1.32 ± 0.67	---		64.6 ± 8.1	121.9 ± 3.2	---	---	
Poly(l-lactic acid)+Polyethylene glycol+ 10% Ibuprofen	1.25 ± 0.59	---		61.6 ± 5.3	123.7 ± 2.6	---	---	
Poly(lactic-co-glycolic acid) + Ibuprofen	300±500	---		---	---	---	---	(38)

Structural properties of profen loaded nanofibrous mats will be reported in Table 4.

9. Kinetics of profen releasing from the nanofibrous webs

Table 5 represented the regression coefficients of mathematical models fitted to the releasing of profens from the nanofibrous mats.

10 .Conclusions and future perspectives

This review has widely presented releasing approaches of the propionic acid derivative drugs (profens) from nanofibrous drug delivery systems. Nanofibers can be used to deliver drugs, so as these ultra-fine structures are the novel materials that are capable as profen carriers in human body for numerous usages, for instance wound dressings. Moreover, they are appropriate for using in surgical sutures for pain reducing.

Conflict of Interest

None declared.

Table 5. Suitable mathematical models fitted to the releasing of profen drugs from the nanofibrous webs.

Nanofibrous web	Mathematical model	Closeness of fit (R2)	Ref
Poly(ethylene glycole) + Silk + Collagen + Flurbiprofen + Vancomycin	Wei-bull	0.99	(51)
Poly(N-vinylcaprolactam) + Ketoprofen	Korshmeyer–Peppas	0.9695	(52)
Poly(lactic-co-glycolic acid) + Poly(vinyl pyrrolidone) + Flurbiprofen	First order	0.9820	(53)
Chitosan + Polyaniline + Ketoprofen	Zero order	0.606	(54)
		0.550	
		0.502	
	First order	0.80	
		0.954	
		0.971	
	Higuchi	0.967	
		0.993	
		0.989	
	Hixson–Crowell	0.708	
		0.834	
		0.856	
	Korsmeyer–Peppas	0.982	
		0.992	
		0.980	
Polyvinylpyrrolidone + Ethyl cellulose + 20% Naproxen		0.9935	(58)
Cellulose + 3% Ibuprofen		0.9388	(59)
Cellulose + 2% Ibuprofen		0.9906	
Poly (lactic acid)+ 15 mg Ibuprofen	Korsmeyer–Peppas	---	(81)
Poly (lactic acid)+ 10 mg Ibuprofen	Korsmeyer–Peppas		
Poly (lactic acid)+ 5 mg Ibuprofen	Korsmeyer–Peppas		
Poly(vinyl alcohol)+Chitason+Ibuprofen	Korsmeyer–Peppas	0.96824	(82)

References

1. Doostmohammadi M, Forootanfar H, Ramakrishna S. Regenerative medicine and drug delivery: Progress via electrospun biomaterials. *Mater Sci Eng: C.* 2020;109:110521.

2. Celebioglu A, Uyar T. Hydrocortisone/cyclodextrin complex electrospun nanofibers for a fast-dissolving oral drug delivery system. *RSC*

Med Chem. 2020;11(2):245-258. Published 2020 Jan 8. doi:10.1039/c9md00390h
3. Nagiah N, Murdock CJ, Bhattacharjee M, Nair L, Laurencin CT. Development of Tripolymeric Triaxial Electrospun Fibrous Matrices for Dual Drug Delivery Applications. *Sci Rep.* 2020;10 (1):609.
4. Sofi HS, Abdal-hay A, Ivanovski S, Zhang YS, Sheikh FA. Electrospun nanofibers for the delivery of active drugs through nasal, oral and vaginal mucosa: Current status and future perspectives. *Mater Sci Eng: C.* 2020;111:110756.
5. Guo H, Tan S, Gao J, Wang L. Sequential release of drugs form a dual-delivery system based on pH-responsive nanofibrous mats towards wound care. *J Mater Chem B*. 2020;8(8):1759-1770.
6. Contreras-Cáceres R, Cabeza L, Perazzoli G, Díaz A, López-Romero JM, Melguizo C, et al. Electrospun Nanofibers: Recent Applications in Drug Delivery and Cancer *Therapy. Nanomaterials (Basel)*. 2019 Apr 24;9(4):656. doi: 10.3390/nano9040656. PMID: 31022935; PMCID: PMC6523776.
7. Kajdič S, Zupančič Š, Roškar R, Kocbek P. The potential of nanofibers to increase solubility and dissolution rate of the poorly soluble and chemically unstable drug lovastatin. *Int J Pharm*. 2020 Jan 5;573:118809. doi: 10.1016/j.ijpharm.2019.118809. Epub 2019 Oct 31. PMID: 31678525.
8. Gupta P, Purwar R. Electrospun pH responsive poly (acrylic acid-co- acrylamide) hydrogel nanofibrous mats for drug delivery. *J Polym Res.* 2020;27 (10):296.
9. Yang J, Wang K, Yu D-G, Yang Y, Bligh SWA, Williams GR. Electrospun Janus nanofibers loaded with a drug and inorganic nanoparticles as an effective antibacterial wound dressing. *Mat Sci Eng: C.* 2020;111:110805.
10. Cleeton C, Keirouz A, Chen X, Radacsi N. Electrospun Nanofibers for Drug Delivery and Biosensing. *ACS Biomater Sci Eng.* 2019 Sep 9;5(9):4183-4205. doi: 10.1021/acsbiomaterials.9b00853. Epub 2019 Aug 23. PMID: 33417777.
11. Tort S, Han D, Steckl AJ. Self-inflating floating nanofiber membranes for controlled drug delivery. *Int J Pharm.* 2020;579:119164.
12. Sa'adon S, Abd Razak SI, Ismail AE, Fakhruddin K. Drug-Loaded Poly-Vinyl Alcohol Electrospun Nanofibers for Transdermal Drug Delivery: Review on Factors Affecting the Drug Release. *Procedia Comput Sci.* 2019;158:436-442.
13. Khodadadi M, Alijani S, Montazeri M, Esmaeilizadeh N, Sadeghi-Soureh S, Pilehvar-Soltanahmadi Y. Recent advances in electrospun nanofiber-mediated drug delivery strategies for localized cancer chemotherapy. *J Biomed Mater Res.* 2020;108 (7):1444-1458.
14. Kharaghani D, Gitigard P, Ohtani H, Kim KO, Ullah S, Saito Y, Khan MQ, Kim IS. Design and characterization of dual drug delivery based on in-situ assembled PVA/PAN core-shell nanofibers for wound dressing application. *Sci Rep.* 2019;9 (1):12640.
15. Huang CK, Zhang K, Gong Q, Yu DG, Wang J, Tan X, Quan H. Ethylcellulose-based drug nano depots fabricated using a modified triaxial electrospinning. *Int J Biol Macromol.* 2020 Jun 1;152:68-76. doi: 10.1016/j.ijbiomac.2020.02.239. Epub 2020 Feb 22. PMID: 32097744.
16. Tavanaie MA. Drug Delivery of Nanofibers Based on Biodegradable Synthetic Polymer Blends: A Review. *Basparesh*. 2017;7 (2):13-29.
17. Yan E, Jiang J, Yang X, Fan L, Wang Y, An Q, Zhang Z, Lu B, Wang D, Zhang D. pH-sensitive core-shell electrospun nanofibers based on polyvinyl alcohol/polycaprolactone as a potential drug delivery system for the chemotherapy against cervical cancer. *J Drug Deliv Sci Technol.* 2020;55:101455.
18. Yang Y, Chang S, Bai Y, Du Y, Yu D-G. Electrospun triaxial nanofibers with middle blank cellulose acetate layers for accurate dual-stage drug release. *Carbohydr Polym*. 2020;243:116477.
19. Hou J, Yang J, Zheng X, Wang M, Liu Y, Yu D-G. A nanofiber-based drug depot with high drug loading for sustained release. *Int J Pharm.* 2020;583:119397.
20. Jain R, Shetty S, Yadav KS. Unfolding the electrospinning potential of biopolymers for preparation of nanofibers. *J Drug Deliv Sci Technol.* 2020;57:101604.
21. Sun Y, Cheng S, Lu W, Wang Y, Zhang P, Yao Q. Electrospun fibers and their application in drug controlled release, biological dressings, tissue repair, and enzyme immobilization. *RSC Adv.* 2019;9 (44):25712-25729.
22. Ismail HM, Ali-Adib S, Younes HM. Re-

active and functionalized electrospun polymeric nanofibers for drug delivery and tissue engineering applications. *Ther Deliv.* 2019 Jul;10(7):397-399. doi: 10.4155/tde-2019-0028. Epub 2019 Jul 15. PMID: 31304876.
23. Moydeen AM, Ali Padusha MS, Aboelfetoh EF, Al-Deyab SS, El-Newehy MH. Fabrication of electrospun poly(vinyl alcohol)/dextran nanofibers via emulsion process as drug delivery system: Kinetics and in vitro release study. *Int J Biol Macromol.* 2018;116:1250-1259.
24. Unnithan AR, Sasikala AR, Murugesan P, Gurusamy M, Wu D, Park CH, et al. Electrospun polyurethane-dextran nanofiber mats loaded with Estradiol for post-menopausal wound dressing. *Int J Biol Macromol.* 2015;77:1-8. doi: 10.1016/j.ijbiomac.2015.02.044. Epub 2015 Mar 5. PMID: 25748849.
25. Faraji Dizaji B, Hasani Azerbaijan M, Sheisi N, Goleij P, Mirmajidi T, Chogan F, Irani M, Sharafian F. Synthesis of PLGA/chitosan/zeolites and PLGA/chitosan/metal organic frameworks nanofibers for targeted delivery of Paclitaxel toward prostate cancer cells death. *Int J Biol Macromol.* 2020;164:1461-1474.
26. Tuğcu-Demiröz F, Saar S, Tort S, Acartürk F. Electrospun metronidazole-loaded nanofibers for vaginal drug delivery. *Drug Dev Ind Pharm.* 2020 Jun;46(6):1015-1025. doi: 10.1080/03639045.2020.1767125. Epub 2020 May 25. PMID: 32393132.
27. Göttel B, de Souza e Silva JM, Santos de Oliveira C, Syrowatka F, Fiorentzis M, Viestenz A, Viestenz A, Mäder K. Electrospun nanofibers – A promising solid in-situ gelling alternative for ocular drug delivery. *Eur J Pharm Biopharm.* 2020;146:125-132.
28. Farokhi M, Mottaghitalab F, Reis RL, Ramakrishna S, Kundu SC. Functionalized silk fibroin nanofibers as drug carriers: Advantages and challenges. *J Control Release.* 2020 May 10;321:324-347. doi: 10.1016/j.jconrel.2020.02.022. Epub 2020 Feb 13. PMID: 32061791.
29. Zandi N, Lotfi R, Tamjid E, Shokrgozar MA, Simchi A. Core-sheath gelatin based electrospun nanofibers for dual delivery release of biomolecules and therapeutics. *Mater Sci Eng C Mater Biol Appl.* 2020 Mar;108:110432. doi: 10.1016/j.msec.2019.110432. Epub 2019 Nov 15. PMID: 31923974.
30. Meneguin AB, da Silva Barud H, Sábio RM, de Sousa PZ, Manieri KF, de Freitas LAP, Pacheco G, Alonso JD, Chorilli M. Spray-dried bacterial cellulose nanofibers: A new generation of pharmaceutical excipient intended for intestinal drug delivery. *Carbohydr Polym*. 2020;249:116838.
31. Khalili Amand F, Esmaeili A. Investigating the properties of electrospun nanofibers made of hybride polymer containing anticoagulant drugs. *Carbohydr Polym.* 2020;228:115397.
32. Jiang Y-N, Mo H-Y, Yu D-G. Electrospun drug-loaded core–sheath PVP/zein nanofibers for biphasic drug release. *Int J Pharm.* 2012;438 (1):232-239.
33. Day RO, Graham GG, Williams K. Propionic Acid Derivative Drugs (Profens). In: Parnham MJ, ed. Compendium of Inflammatory Diseases. Basel: Springer Basel; 2016:1106-1110.
34. Duggan KC, Hermanson DJ, Musee J, et al. (R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2. *Nat Chem Biol.* 2011;7(11):803-809. doi:10.1038/nchembio.663
35. Mao Y, Chen M, Guidoin R, Li Y, Wang F, Brochu G, Zhang Z, Wang L. Potential of a facile sandwiched electrospun scaffold loaded with ibuprofen as an anti-adhesion barrier. *Mater Sci Eng C Mater Biol Appl.* 2021 Jan;118:111451. doi: 10.1016/j.msec.2020.111451. Epub 2020 Aug 27. PMID: 33255038.
36. Chen CT, Chen CH, Sheu C, Chen JP. Ibuprofen-Loaded Hyaluronic Acid Nanofibrous Membranes for Prevention of Postoperative Tendon Adhesion through Reduction of Inflammation. *Int J Mol Sci.* 2019 Oct 11;20(20):5038. doi: 10.3390/ijms20205038. PMID: 31614502; PMCID: PMC6834315.
37. Xu Y, Li JJ, Yu DG, Williams GR, Yang JH, Wang X. Influence of the drug distribution in electrospun gliadin fibers on drug-release behavior. *Eur J Pharm Sci.* 2017 Aug 30;106:422-430. doi: 10.1016/j.ejps.2017.06.017. Epub 2017 Jun 11. PMID: 28614732.
38. Jamshidi-Adegani F, Seyedjafari E, Gheibi N, Soleimani M, Sahmani M. Prevention of adhesion bands by ibuprofen-loaded PLGA nanofibers. *Biotechnol Prog.* 2016 Jul 8;32(4):990-7. doi: 10.1002/btpr.2270. Epub 2016 Aug 3. PMID: 27061396.
39. Yu D-G, Zhang X-F, Shen X-X, Brand-

ford-White C, Zhu L-M. Ultrafine ibuprofen-loaded polyvinylpyrrolidone fiber mats using electrospinning. *Polym Int.* 2009;58 (9):1010-1013.
40. Shi Y, Wei Z, Zhao H, Liu T, Dong A, Zhang J. Electrospinning of ibuprofen-loaded composite nanofibers for improving the performances of transdermal patches. *J Nanosci Nanotechnol.* 2013 Jun;13(6):3855-63. doi: 10.1166/jnn.2013.7157. PMID: 23862418.
41. Chen S, Wang G, Wu T, et al. Silver nanoparticles/ibuprofen-loaded poly(L-lactide) fibrous membrane: anti-infection and anti-adhesion effects. *Int J Mol Sci.* 2014;15(8):14014-14025. Published 2014 Aug 12. doi:10.3390/ijms150814014
42. Tran T, Hernandez M, Patel D, Burns E, Peterman V, Wu J. Controllable and switchable drug delivery of ibuprofen from temperature responsive composite nanofibers. *Nano Convergence.* 2015;2 (1):15.
43. Liu S, Hu C, Li F, Li XJ, Cui W, Fan C. Prevention of peritendinous adhesions with electrospun ibuprofen-loaded poly(L-lactic acid)-polyethylene glycol fibrous membranes. *Tissue Eng Part A*. 2013;19(3-4):529-37.
44. Mohiti-Asli M, Saha S, Murphy SV, Gracz H, Pourdeyhimi B, Atala A, Loboa EG. Ibuprofen loaded PLA nanofibrous scaffolds increase proliferation of human skin cells in vitro and promote healing of full thickness incision wounds in vivo. *J Biomed Mater Res B Appl Biomater.* 2017 Feb;105(2):327-339. doi: 10.1002/jbm.b.33520. Epub 2015 Oct 28. PMID: 26509902.
45. Shi Y, Xu S, Dong A, Zhang J. Design and in vitro evaluation of transdermal patches based on ibuprofen-loaded electrospun fiber mats. *J Mater Sci Mater Med.* 2013 Feb;24(2):333-41. doi: 10.1007/s10856-012-4805-1. Epub 2012 Nov 9. PMID: 23138838.
46. Potrč T, Baumgartner S, Roškar R, Planinšek O, Lavrič Z, Kristl J, Kocbek P. Electrospun polycaprolactone nanofibers as a potential oromucosal delivery system for poorly water-soluble drugs. *Eur J Pharm Sci.* 2015 Jul 30;75:101-13. doi: 10.1016/j.ejps.2015.04.004. Epub 2015 Apr 21. PMID: 25910438.
47. Gao Y, Teoh TW, Wang Q, Williams GR. Electrospun organic–inorganic nanohybrids as sustained release drug delivery systems. *J Mater Chem B*. 2017;5 (46):9165-9174.
48. Li Z, Kang H, Che N, Liu Z, Li P, Li W, et al. Controlled release of liposome-encapsulated Naproxen from core-sheath electrospun nanofibers. *Carbohydr Polym.* 2014 Oct 13;111:18-24. doi: 10.1016/j.carbpol.2014.04.017. Epub 2014 Apr 18. PMID: 25037324.
49. Yu D-G, Branford-White C, Shen X-X, Zhang X-F, Zhu L-M. Solid Dispersions of Ketoprofen in Drug-Loaded Electrospun Nanofibers. *J Dispers Sci Technol*. 2010;31 (7):902-908.
50. Kenawy E-R, Abdel-Hay FI, El-Newehy MH, Wnek GE. Controlled release of ketoprofen from electrospun poly(vinyl alcohol) nanofibers. *Mater Sci Engin: A.* 2007;459 (1):390-396.
51. Wen S, Hu Y, Zhang Y, Huang S, Zuo Y, Min Y. Dual-functional core-shell electrospun mats with precisely controlled release of anti-inflammatory and anti-bacterial agents. *Mater Sci Eng C Mater Biol Appl.* 2019 Jul;100:514-522. doi: 10.1016/j.msec.2019.02.076. Epub 2019 Feb 23. PMID: 30948088.
52. Sta M, Aguiar G, Forni AAJ, Medeiros SF, Santos AM, Demarquette NR. Design and characterization of PNVCL-based nanofibers and evaluation of their potential applications as scaffolds for surface drug delivery of hydrophobic drugs. *J Appl Polym Sci.* 2020;137 (11):48472.
53. Zhu T, Chen S, Li W, Lou J, Wang J. Flurbiprofen axetil loaded coaxial electrospun poly(vinyl pyrrolidone)–nanopoly(lactic-co-glycolic acid) core–shell composite nanofibers: Preparation, characterization, and anti-adhesion activity. *J Appl Polym Sci.* 2015;132 (22).
54. Minisy IM, Salahuddin NA, Ayad MM. In vitro release study of ketoprofen-loaded chitosan/polyaniline nanofibers. *Polym Bull.* 2020.
55. Lee H, Xu G, Kharaghani D, Nishino M, Song KH, Lee JS, et al. Electrospun tri-layered zein/PVP-GO/zein nanofiber mats for providing biphasic drug release profiles. *Int J Pharm.* 2017 Oct 5;531(1):101-107. doi: 10.1016/j.ijpharm.2017.08.081. Epub 2017 Aug 19. PMID: 28830784.
56. Vrbata P, Berka P, Stránská D, Doležal P, Musilová M, Čižinská L. Electrospun drug loaded membranes for sublingual administration of sumatriptan and naproxen. *Int J Pharm.* 2013 Nov 30;457(1):168-76. doi: 10.1016/j.ijpharm.2013.08.085. Epub 2013 Sep 16. PMID: 24050988.

57. Riggin CN, Qu F, Kim DH, Huegel J, Steinberg DR, Kuntz AF, Soslowsky LJ, Mauck RL, Bernstein J. Electrospun PLGA Nanofiber Scaffolds Release Ibuprofen Faster and Degrade Slower After In Vivo Implantation. *Ann Biomed Eng*. 2017 Oct;45(10):2348-2359. doi: 10.1007/s10439-017-1876-7. Epub 2017 Jun 26. PMID: 28653294; PMCID: PMC5831397.
58. Godakanda VU, Li H, Alquezar L, Zhao L, Zhu L-M, de Silva R, de Silva KMN, Williams GR. Tunable drug release from blend poly(vinyl pyrrolidone)-ethyl cellulose nanofibers. *Int J Pharm.* 2019;562:172-179.
59. Liu Y, Nguyen A, Allen A, Zoldan J, Huang Y, Chen JY. Regenerated cellulose micro-nano fiber matrices for transdermal drug release. *Mater Sci Engin: C*. 2017;74:485-492.
60. Tarlani A, Isari M, Khazraei A, Eslami Moghadam M. New sol-gel derived aluminum oxide-ibuprofen nanocomposite as a controlled releasing medication. *Nanomedi Res J.* 2017;2 (1):28-35.
61. Raimi-Abraham BT, Mahalingam S, Davies PJ, Edirisinghe M, Craig DQ. Development and Characterization of Amorphous Nanofiber Drug Dispersions Prepared Using Pressurized Gyration. *Mol Pharm*. 2015 Nov 2;12(11):3851-61. doi: 10.1021/acs.molpharmaceut.5b00127. Epub 2015 Oct 6. PMID: 26402331.
62. Nabipour Z, Nourbakhsh MS, Baniasadi M. Evaluation of Ibuprofen Release from Gelatin / Hydroxyapatite /Polylactic Acid Nanocomposites. *Iran J Pharm Sci.* 2018;14 (1):75-84.
63. Mao Y, Chen M, Guidoin R, Li Y, Wang F, Brochu G, et al. Potential of a facile sandwiched electrospun scaffold loaded with ibuprofen as an anti-adhesion barrier. *Mater Sci Eng C*. 2021;118:111451.
64. Qirui H, Xiang LQ. Synthesis of Electrospun Zein and Silk Fibroin/Zein Meshes with Ibuprofen for Drug Delivery to Chronic Wounds. Thesis, 2018.
65. SATRIAWAN NE. Sintesis Dan Karakterisasi Nanofiber Selulosa Asetat Penambahan Ibuprofen Sebagai Model Sistem Penghantar Obat. Thesis , Universitas Airlangga, 2017.
66. Batool F, Morand DN, Thomas L, Bugueno IM, Aragon J, Irusta S, et al. Synthesis of a Novel Electrospun Polycaprolactone Scaffold Functionalized with Ibuprofen for Periodontal Regeneration: An In Vitro andIn Vivo Study. *Materials (Basel)*. 2018 Apr 10;11(4):580. doi: 10.3390/ma11040580. PMID: 29642582; PMCID: PMC5951464.
67. Yuan Z, Zhao J, Zhu W, Yang Z, Li B, Yang H, et al. Ibuprofen-loaded electrospun fibrous scaffold doped with sodium bicarbonate for responsively inhibiting inflammation and promoting muscle wound healing in vivo. *Biomater Sci.* 2014;2 (4):502-511.
68. Wang L, Chen D, Sun J. Layer-by-layer deposition of polymeric microgel films on surgical sutures for loading and release of ibuprofen. *Langmuir.* 2009 Jul 21;25(14):7990-4. doi: 10.1021/la9004664. PMID: 19326871.
69. Yuan Z, Zhao J, Yang Z, Li B, Yang H, Cui W, et al. Synergistic Effect of Regeneration and Inflammation via Ibuprofen-Loaded Electrospun Fibrous Scaffolds for Repairing Skeletal Muscle. *Eur J Inflamm*. 2014;12 (1):41-52. doi:10.1177/1721727X1401200105
70. Cantón I, Mckean R, Charnley M, Blackwood KA, Fiorica C, Ryan AJ, MacNeil S. Development of an Ibuprofen-releasing biodegradable PLA/PGA electrospun scaffold for tissue regeneration. *Biotechnol Bioeng.* 2010 Feb 1;105(2):396-408. doi: 10.1002/bit.22530. PMID: 19731254.
71. Tungprapa S, Jangchud I, Supaphol P. Release characteristics of four model drugs from drug-loaded electrospun cellulose acetate fiber mats. *Polym*. 2007;48 (17):5030-5041.
72. Jiang H, Fang D, Hsiao B, Chu B, Chen W. Preparation and characterization of ibuprofen-loaded poly(lactide-co-glycolide)/poly(ethylene glycol)-g-chitosan electrospun membranes. *J Biomater Sci Polym Ed.* 2004;15(3):279-96. doi: 10.1163/156856204322977184. PMID: 15147162.
73. Sequeira RS, Miguel SP, Cabral CSD, Moreira AF, Ferreira P, Correia IJ. Development of a poly(vinyl alcohol)/lysine electrospun membrane-based drug delivery system for improved skin regeneration. *Int J Pharm.* 2019;570:118640.
74. Yang Y, Li W, Yu DG, Wang G, Williams GR, Zhang Z. Tunable drug release from nanofibers coated with blank cellulose acetate layers fabricated using tri-axial electrospinning. *Carbohydr Polym.* 2019 Jan 1;203:228-237. doi: 10.1016/j.carbpol.2018.09.061. Epub 2018 Sep 26. PMID: 30318208.
75. Maslakci NN, Ulusoy S, Uygun E,

Çevikbaş H, Oksuz L, Can HK, Uygun Oksuz A. Ibuprofen and acetylsalicylic acid loaded electrospun PVP-dextran nanofiber mats for biomedical applications. *Polym Bull.* 2017;74 (8):3283-3299.
76. Shalumon KT, Sheu C, Chen CH, Chen SH, Jose G, Kuo CY, et al. Multi-functional electrospun antibacterial core-shell nanofibrous membranes for prolonged prevention of post-surgical tendon adhesion and inflammation. *Acta Biomater.* 2018 May;72:121-136. doi: 10.1016/j.actbio.2018.03.044. Epub 2018 Apr 5. PMID: 29626695.
77. Hu C, Liu S, Zhang Y, Li B, Yang H, Fan C, et al. Long-term drug release from electrospun fibers for in vivo inflammation prevention in the prevention of peritendinous adhesions. *Acta Biomater.* 2013 Jul;9(7):7381-8. doi: 10.1016/j.actbio.2013.03.040. Epub 2013 Apr 6. PMID: 23567943.
78. Luraghi A, Peri F, Moroni L. Electrospinning for drug delivery applications: A review. *J Control Release*. 2021;334:463-84.
79. Sahmani S, Khandan A, Saber-Samandari S, Mohammadi Aghdam M. Effect of magnetite nanoparticles on the biological and mechanical properties of hydroxyapatite porous scaffolds coated with ibuprofen drug. *Mater Sci Engin: C.* 2020;111:110835.
80. Celebioglu A, Uyar T. Fast Dissolving Oral Drug Delivery System Based on Electrospun Nanofibrous Webs of Cyclodextrin/Ibuprofen Inclusion Complex Nanofibers. *Mol Pharmaceutics.* 2019;16 (10):4387-4398.
81. Immich APS, Arias ML, Carreras N, Boemo RL, Tornero JA. Drug delivery systems using sandwich configurations of electrospun poly(lactic acid) nanofiber membranes and ibuprofen. *Mater Sci Engin: C.* 2013;33 (7):4002-4008.
82. Celik G, Oksuz AU. Controlled Release of Ibuprofen From Electrospun Biocompatible Nanofibers With In Situ QCM Measurements. *J Macromol Sci A*. 2015;52 (1):76-83.